CJC-1295 (DAC)

CJC-1295 DAC (5mg) — Long-Acting GHRH Analogue Research Peptide

CJC-1295 DAC (5mg) is supplied in Australia by Omega Peptides Australia from domestic stock, with same-day dispatch on orders placed before 12pm and an independent certificate of analysis for every batch. Commonly written as CJC 1295 DAC, CJC1295 DAC, CJC DAC, CJC with DAC, CJC-1295 with DAC or CJC 1295 with DAC, it is a long-acting GHRH analogue with a drug affinity complex studied for sustained growth hormone release.

CJC-1295 with DAC is a synthetic thirty-amino-acid analogue of the first 29 residues of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary to release growth hormone. It carries four amino-acid substitutions that protect it from enzymatic breakdown, plus a C-terminal lysine bearing a maleimidopropionic acid linker known as the Drug Affinity Complex, or DAC. It is written as CJC1295 DAC, CJC-1295 with DAC or cjc 1295 dac, and is sometimes called DAC:GRF or Drug Affinity Complex GRF. It was developed by the Canadian biotechnology company ConjuChem.

CJC-1295 DAC is studied for sustained growth hormone and IGF-1 signalling, for the pharmacology of albumin-binding peptide conjugates, and as a long-acting comparator for shorter GHRH analogues such as sermorelin and Modified GRF (1-29). At the receptor level it is an agonist of the GHRH receptor on pituitary somatotroph cells, where it raises cyclic AMP and drives growth hormone synthesis and release; the DAC linker forms a covalent bond with circulating albumin, which shields the peptide from clearance and extends its half-life from minutes to days.

Omega Peptides Australia supplies CJC-1295 DAC as a high-purity (≥99% HPLC) COA-verified lyophilised powder in a 5mg vial, dispatched same day from within Australia on orders placed before 12pm. Every batch is independently tested and the certificate for your vial can be reviewed in our COA library before you order.

Key research areas

• Sustained growth hormone release CJC-1295 DAC is the standard model compound for studying prolonged GHRH-receptor stimulation. Early clinical pharmacology work reported that a single administration raised growth hormone and IGF-1 levels for well over a week, and it is used in research to examine how continuous GHRH signalling interacts with the pituitary's natural pulsatile release pattern.
• IGF-1 and downstream signalling Because growth hormone acts largely through hepatic IGF-1, CJC-1295 DAC is used in models of the GH-IGF-1 axis to study IGF-1 production, binding-protein changes and feedback regulation over multi-day time courses that short-acting analogues cannot reach.
• Albumin-conjugation pharmacology The DAC technology is a well-known example of covalent albumin binding used to extend peptide half-life. CJC-1295 DAC is studied as a reference for bioconjugation chemistry, maleimide-thiol coupling and the pharmacokinetics of albumin-bound drugs.
• Body-composition and metabolic research Growth hormone influences lipolysis, protein synthesis and glucose handling, and CJC-1295 DAC has been examined in preclinical and early clinical programmes for lipodystrophy and growth hormone deficiency, making it a reference compound in metabolic research.
• Comparative GHRH-analogue studies Researchers use CJC-1295 DAC alongside sermorelin, Modified GRF (1-29) and tesamorelin to compare receptor potency, enzymatic stability and duration of action across the GHRH-analogue family.
• Secretagogue combination research GHRH analogues and ghrelin-receptor agonists such as ipamorelin act on different receptors, and their combined effect on growth hormone output is a recurring research question. CJC-1295 DAC is studied as the long-acting GHRH component in such models.

How CJC-1295 DAC works

Native GHRH binds the GHRH receptor, a G-protein-coupled receptor on pituitary somatotrophs, and activates adenylyl cyclase, raising intracellular cyclic AMP and triggering both the synthesis and the release of growth hormone. Native GHRH is broken down within minutes by dipeptidyl peptidase-IV and other proteases. CJC-1295 addresses this with four substitutions in the GHRH(1-29) backbone: D-alanine at position 2 blocks DPP-IV cleavage, glutamine at position 8 reduces asparagine deamidation, alanine at position 15 improves receptor affinity and stability, and leucine at position 27 prevents methionine oxidation. The DAC component then adds a lysine carrying a maleimidopropionic acid group at the C-terminus, and this maleimide reacts with the free thiol of cysteine-34 on serum albumin to form a stable covalent conjugate.

Once bound to albumin the peptide is protected from renal filtration and enzymatic degradation, and its half-life in early human pharmacology studies was reported at roughly six to eight days. This is the defining difference between the DAC and No DAC forms: Modified GRF (1-29), sold here in the CJC-1295 No DAC and Ipamorelin blend, has the same four substitutions but no albumin-binding linker, so it acts for around thirty minutes and produces a short pulse of growth hormone rather than a sustained elevation. In research, DAC is chosen when a steady, prolonged GHRH signal is wanted and No DAC when pulsatility needs to be preserved.

Specifications

Available sizes and pricing

CJC-1295 DAC is supplied in a single 5mg vial. Because the molecule is large, at about 3647 g/mol, 5mg corresponds to roughly 1.4 micromoles, and because the albumin-bound conjugate persists for days, research designs typically consume far less material per time point than with short-acting analogues. Researchers comparing DAC and No DAC forms can pair this vial with the CJC-1295 No DAC and Ipamorelin blend at $139.99.

• 5mg vial — $89.99 (about $18.00 per mg)

Quality and COA verification

Every batch of CJC-1295 DAC is independently tested by Janoshik Analytical. HPLC is used to confirm purity at or above 99% and mass spectrometry is used to confirm identity, which is particularly important for this compound because DAC and No DAC forms differ by only a single modified residue and are frequently mislabelled in the marketplace. A Certificate of Analysis is issued for every batch and published in our COA library, so the result for the vial you receive can be checked against its batch number. The peptide is supplied as a lyophilised powder in a sealed sterile vial for stability in storage and transit, and each order is packed securely and discreetly for domestic delivery within Australia.

Frequently bought together

• CJC-1295 No DAC + Ipamorelin Blend (10mg) — $139.99, the short-acting GHRH analogue paired with a selective secretagogue for DAC versus No DAC comparisons
• Ipamorelin (10mg) — $89.99, a ghrelin-receptor agonist that acts on a separate pathway from GHRH analogues
• Sermorelin (5mg) — $89.99, the unmodified GHRH(1-29) reference compound for potency and stability comparisons
• Bacteriostatic Water (10mL) — $29.99, the recommended diluent for reconstituting lyophilised peptides

Research guides

• CJC-1295 and Ipamorelin research guide
• How to reconstitute peptides
• Sermorelin research guide
• How to store lyophilised peptides
• COA testing explained
• Peptide reconstitution calculator

Frequently asked questions

What is CJC-1295 DAC?
CJC-1295 DAC is a synthetic analogue of growth hormone-releasing hormone made up of a modified GHRH(1-29) sequence joined to a Drug Affinity Complex, a lysine-linked maleimide group that binds covalently to albumin in the blood. The albumin binding extends its activity from minutes to days. Omega Peptides Australia supplies it as a COA-verified lyophilised powder in a 5mg vial strictly for in-vitro laboratory research.

What is CJC-1295 DAC also known as?
It is also written as CJC1295 DAC, CJC DAC, CJC-1295 with DAC, CJC 1295 with DAC or cjc 1295 dac, and appears in the scientific literature as DAC:GRF or Drug Affinity Complex GRF. Its CAS number is 446262-90-4. The name CJC-1295 on its own is frequently used for the No DAC form, Modified GRF (1-29), which is a different compound with CAS number 863288-34-0.

How does CJC-1295 DAC work?
It activates the GHRH receptor on pituitary somatotroph cells, raising cyclic AMP and stimulating growth hormone synthesis and release, which in turn increases hepatic IGF-1 production. Four amino-acid substitutions protect it from DPP-IV and oxidative breakdown, and the maleimide group of the DAC linker bonds to cysteine-34 on serum albumin, so the peptide circulates as an albumin conjugate with a half-life reported at about six to eight days.

What does the research show about CJC-1295 DAC?
Early clinical pharmacology studies run during its development for lipodystrophy and growth hormone deficiency reported multi-fold increases in growth hormone and IGF-1 lasting more than a week after a single administration, and the programme reached Phase 2 before it was discontinued. In current research the compound is used to study prolonged GHRH signalling, the GH-IGF-1 axis and albumin-conjugate pharmacokinetics.

Can I buy CJC-1295 DAC at Chemist Warehouse or a pharmacy in Australia?
No. CJC-1295 DAC is not a registered medicine in Australia and is not stocked by Chemist Warehouse, Priceline or any other retail pharmacy. The material supplied here is a research-grade lyophilised compound with an independent batch Certificate of Analysis, intended for laboratory use, and it is not a pharmacy product.

Can Australian compounding pharmacies supply CJC-1295 DAC?
CJC-1295 has in the past been among the peptides some Australian compounding pharmacies prepared on prescription. Compounding is only permitted for an individual patient on a valid prescription from a registered prescriber, within Pharmacy Board and TGA rules, and the TGA has stepped up compliance action on unapproved peptide products. Omega Peptides Australia is not a pharmacy. We supply the lyophilised research compound with a batch COA for in-vitro laboratory work only.

How do you reconstitute CJC-1295 DAC?
Use bacteriostatic water. Let the vial reach room temperature, then add the water slowly down the inside wall so it runs onto the powder without splashing. Swirl gently until dissolved, do not shake. The DAC linker can make dissolution a little slower than with unmodified peptides, so allow the vial a few extra minutes and swirl again if needed. Refrigerate at 2 to 8°C and use within 28 days.

How should CJC-1295 DAC be stored?
Keep sealed lyophilised vials at 2 to 8°C for short-term storage or at minus 20°C for long-term storage, protected from light and moisture, and avoid repeated freeze-thaw cycles. The dry powder is stable for extended periods under these conditions. After reconstitution, store the solution in the refrigerator at 2 to 8°C and use within 28 days.

Where can I buy CJC-1295 DAC in Australia?
CJC-1295 DAC can be ordered directly from Omega Peptides Australia. Stock is held domestically, orders placed before 12pm are dispatched the same day with tracked shipping, and every batch has an independent Janoshik COA available in our library. Related GHRH analogues and secretagogues can be found in our range of research peptides in Australia if you are ordering for a comparative study.

What does CJC-1295 DAC cost in Australia?
CJC-1295 DAC is $89.99 for a 5mg vial, which works out at about $18.00 per mg. Although the price per mg is higher than for smaller peptides, the long duration of the albumin-bound conjugate means research designs generally use less material per time point. The No DAC form is available in the CJC-1295 No DAC and Ipamorelin blend at $139.99 for a 10mg vial.

How do I get CJC-1295 DAC online in Australia?
Select the 5mg vial on this page, add it to your cart and complete checkout. Orders ship from our Australian stock with tracked domestic delivery in discreet packaging, and orders placed before 12pm on a business day are dispatched the same day. Because the product ships from within Australia there is no customs clearance or import paperwork and delivery times are short.

Is CJC-1295 DAC legal in Australia?
Omega Peptides Australia supplies CJC-1295 DAC strictly for lawful in-vitro laboratory research. It is not approved by the TGA for human or veterinary use and is not sold as a medicine or supplement. Purchasers are responsible for ensuring their intended use complies with all applicable laws.

What is the difference between CJC-1295 DAC and No DAC (Modified GRF 1-29)?
Both share the same modified GHRH(1-29) sequence with four stabilising substitutions. The DAC version adds a lysine-linked maleimide that binds covalently to albumin, giving a half-life of days and a sustained growth hormone signal. The No DAC version, Modified GRF (1-29), has no linker, is cleared in about thirty minutes and produces a short pulse. The No DAC form is supplied here in the CJC-1295 No DAC and Ipamorelin blend.

⚠ For in-vitro research and laboratory use only. Not for human or veterinary use.